Wu Xiaobin, President and Chief Operating Officer of BeOne Medicines Ltd. (NASDAQ:ONC), filed a Form 4 on August 27, 2026, disclosing the sale of 280 American Depositary Shares on August 25, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Seller and role: Wu Xiaobin, President and COO of BeOne Medicines Ltd.
  • Transaction: 280 American Depositary Shares sold on August 25, 2026, at a price of $380 per share.
  • Plan: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
  • Remaining direct ADS holdings: 0 American Depositary Shares held directly following the reported transaction.
  • Indirect ADS holdings: 4,000 American Depositary Shares held indirectly by wife.
  • Ordinary Shares: 1,270,084 Ordinary Shares held directly, and 12,365 American Depositary Shares held directly, as reported in the filing.
  • ADS conversion ratio: Each American Depositary Share represents 13 Ordinary Shares, according to the filing.

Wu Xiaobin's ADS Sale and Beneficial Ownership After Transaction

According to the Form 4 filed with the U.S. Securities and Exchange Commission on August 27, 2026, Wu Xiaobin, President and COO of BeOne Medicines Ltd. (NASDAQ:ONC), disposed of 280 American Depositary Shares on August 25, 2026, at a price of $380 per share. The filing indicates the transaction code was "S," denoting a sale, and was carried out under a Rule 10b5-1 trading plan that the reporting person adopted on November 7, 2025.

Following the reported transaction, the filing shows Wu Xiaobin's direct beneficial ownership of American Depositary Shares standing at 0, while his direct holdings of Ordinary Shares are listed at 1,270,084 and direct American Depositary Shares at 12,365. Additionally, 4,000 American Depositary Shares are held indirectly by wife, according to the filing. The filing notes that each American Depositary Share represents 13 Ordinary Shares.

The Form 4 was signed by Chan Henry Lee as Attorney-in-Fact on August 27, 2026, and indicates the filing was made by one reporting person. The filing also notes, via a checked box, that the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

What Was Disclosed

The filing reports a single sale of 280 American Depositary Shares at $380 each by BeOne Medicines' President and COO, executed under a pre-established Rule 10b5-1 plan, with resulting direct ADS holdings of 0 following the transaction.